文献速递糖尿病

糖耐量异常转归与心血管及微血管疾病风险的30年大庆研究

Associations of progression to diabetes and regression to normal glucose tolerance with development of cardiovascular and microvascular disease among people with impaired glucose tolerance: a secondary analysis of the 30 year Da Qing Diabetes Prevention Outcome Study.
PubMed 文献 · Diabetologia · 2021-02-19

基于大庆糖尿病预防研究540例糖耐量异常(IGT)参与者的观察性分析,6年干预结束时46.7%进展为糖尿病、21.1%维持IGT、32.2%逆转为正常糖耐量(NGT)。此后随访24年发现,逆转为NGT或维持IGT者心血管病和微血管病发病率均显著低于进展为糖尿病者。

要点

  • IGT逆转为NGT者心血管病风险较进展为糖尿病者降低37%(HR 0.63;95%CI 0.47,0.85)
  • 逆转为NGT者微血管病风险降低66%(HR 0.34;95%CI 0.20,0.56),发病延迟18.66年
  • 维持IGT者心血管病风险降低34%、微血管病风险降低52%,均显著优于进展为糖尿病者

核心结论

  • IGT人群在6年干预结束时逆转为NGT或维持IGT者,其后24年心血管病和微血管病发病率显著低于进展为糖尿病者。

研究设计与样本

  • 大庆糖尿病预防研究为6年生活方式干预试验,本分析为其中540例IGT参与者的观察性研究。
  • IGT按1985年WHO标准定义:空腹血糖<7.8 mmol/l,且负荷后2小时血糖≥7.8且<11.1 mmol/l。
  • 干预结束后按逆转为NGT、维持IGT或进展为糖尿病分组,继续随访24年。

主要发现

  • 6年试验结束时252例(46.7%)进展为糖尿病,114例(21.1%)维持IGT,174例(32.2%)逆转为NGT。
  • 与试验期间进展为糖尿病者相比,NGT组糖尿病发病中位延迟14.86年(95%CI 12.49,17.25),IGT组延迟9.87年(95%CI 8.12,11.68)。
  • 试验结束后24年,糖尿病、IGT、NGT三组心血管病累积发病率分别为64.5%、48.5%、45.1%,微血管病分别为36.8%、21.7%、16.5%。
  • 与进展为糖尿病者相比,逆转为NGT者心血管病发病中位延迟7.45年(95%CI 1.91,12.99),维持IGT者延迟5.69年(95%CI 1.0,10.38)。
  • 维持IGT者微血管病发病中位延迟12.56年(95%CI 2.49,22.63)。

临床怎么用

  • 对IGT人群应积极干预以促进血糖逆转或维持,而非仅延缓进展为糖尿病,以降低远期心血管和微血管风险。

局限性

  • 本研究为对既往生活方式干预试验的二次分析,分组非随机,属观察性比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We aimed to determine associations of regression to normal glucose tolerance (NGT), maintaining impaired glucose tolerance (IGT) or progression to diabetes with subsequent risks of CVD and microvascular disease among Chinese adults with IGT. METHODS: We conducted an observational study among 540 participants in the Da Qing Diabetes Prevention Study, a 6 year lifestyle intervention trial in people with IGT, defined by 1985 WHO criteria as fasting plasma glucose <7.8 mmol/l and 2 h post-load plasma glucose ≥7.8 and <11.1 mmol/l. At the end of the trial, the groups that had regressed to NGT, remained with IGT or progressed to diabetes were identified. Participants were then followed for 24 years after completion of the trial, during which we compared the incidence and hazard ratios for CVD and microvascular disease in each group and estimated the differences in their median time to onset from parametric Weibull distribution models. RESULTS: At the end of the 6 year trial, 252 (46.7%) participants had developed diabetes, 114 (21.1%) had remained with IGT and 174 (32.2%) had regressed to NGT. Compared with those who developed diabetes during the trial, the median time to onset of diabetes was delayed by 14.86 years (95% CI 12.49, 17.25) in the NGT and 9.87 years (95% CI 8.12, 11.68) in the IGT groups. After completion of the trial, among those with diabetes, IGT and NGT, the 24 year cumulative incidence of CVD was 64.5%, 48.5% and 45.1%, respectively, and 36.8%, 21.7% and 16.5% for microvascular diseases. Compared with participants who had progressed to diabetes during the trial, those who regressed to NGT had a 37% (HR 0.63; 95% CI 0.47, 0.85) reduction in CVD incidence and a median delay of 7.45 years (95% CI 1.91, 12.99) in onset, and those who remained with IGT had a 34% (HR 0.66; 95% CI 0.47, 0.91) lower CVD incidence with a median delay in onset of 5.69 years (95% CI 1.0, 10.38). Participants with NGT had a 66% (HR 0.34; 95% CI 0.20, 0.56) lower incidence of microvascular diseases and a median delay in the onset of 18.66 years (95% CI 6.08, 31.24), and those remaining with IGT had a 52% (HR 0.48; 95% CI 0.29, 0.81) lower incidence with a median delay of 12.56 years (95% CI 2.49, 22.63). CONCLUSIONS/INTERPRETATION: People with IGT who reverted to NGT or remained with IGT at the end of the 6 year trial subsequently had significantly lower incidences of CVD and microvascular disease than those who had developed diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Chen Y, Zhang P, Wang J, et al. Associations of progression to diabetes and regression to normal glucose tolerance with development of cardiovascular and microvascular disease among people with impaired glucose tolerance: a secondary analysis of the 30 year Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2021. PMID: 33608769. doi:10.1007/s00125-021-05401-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。